Published in Gene Therapy Weekly, October 14th, 2004
TKT expects that top-line results of the clinical trial will be available in the first half of 2005. If the data are positive, TKT intends to file an amendment to the European Dynepo product license in order to expand its approved indication to include anemia associated with cancer chemotherapy.
In a March 2004...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.